BDC Capital's life sciences venture fund bolsters Canadian therapeutics and medtech — an underrated pipeline for U.S. and EU follow-on rounds.

Jeito Capital's €1B Fund II cements the case that Europe can fund late-stage biopharma domestically, without exporting all growth-stage capital to the U.S.

Blackstone's opportunistic private credit fund is not VC, but its scale directly changes how venture-backed companies refinance, recapitalize, and exit.

Mega buyout funds like KKR's 2026 vehicle aren't traditional VC, but they materially influence late-stage startup exits and crossover rounds.

Alcatraz's April 2026 round reflects growing demand for privacy-aware biometric access systems in critical facilities.

From NYC seed activity to U.S. AI infrastructure rounds, April 2026 deal flow shows where capital is concentrating and what founders should do next.